|
1
|
Sanderson RJ and Ironside JA: Squamous
cell carcinomas of the head and neck. BMJ. 325:822–827. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chaturvedi AK, Anderson WF,
Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS,
Bray F and Gillison ML: Worldwide trends in incidence rates for
oral cavity and oropharyngeal cancers. J Clin Oncol. 31:4550–4559.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leemans CR, Snijders PJF and Brakenhoff
RH: The molecular landscape of head and neck cancer. Nat Rev
Cancer. 18:269–282. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leemans CR, Braakhuis BJ and Brakenhoff
RH: The molecular biology of head and neck cancer. Nat Rev Cancer.
11:9–22. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oliva M, Spreafico A, Taberna M, Alemany
L, Coburn B, Mesia R and Siu LL: Immune biomarkers of response to
immune-checkpoint inhibitors in head and neck squamous cell
carcinoma. Ann Oncol. 30:57–67. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hira-Miyazawa M, Nakamura H, Hirai M,
Kobayashi Y, Kitahara H, Bou-Gharios G and Kawashiri S: Regulation
of programmed-death ligand in the human head and neck squamous cell
carcinoma microenvironment is mediated through matrix
metalloproteinase-mediated proteolytic cleavage. Int J Oncol.
52:379–388. 2018.PubMed/NCBI
|
|
7
|
Zhou C, Ye M, Ni S, Li Q, Ye D, Li J, Shen
Z and Deng H: DNA methylation biomarkers for head and neck squamous
cell carcinoma. Epigenetics. 13:398–409. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Allameh A, Moazeni-Roodi A, Harirchi I,
Ravanshad M, Motiee-Langroudi M, Garajei A, Hamidavi A and
Mesbah-Namin SA: Promoter DNA methylation and mRNA expression level
of p16 gene in oral squamous cell carcinoma: Correlation with
Clinicopathological Characteristics. Pathol Oncol Res.
25:1535–1543. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fomenkov A, Zangen R, Huang YP, Osada M,
Guo Z, Fomenkov T, Trink B, Sidransky D and Ratovitski EA: RACK1
and stratifin target DeltaNp63alpha for a proteasome degradation in
head and neck squamous cell carcinoma cells upon DNA damage. Cell
Cycle. 3:1285–1295. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mirza AH, Thomas G, Ottensmeier CH and
King EV: Importance of the immune system in head and neck cancer.
Head Neck. 41:2789–2800. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rossa C Jr and D'silva NJ: Immune-relevant
aspects of murine models of head and neck cancer. Oncogene.
38:3973–3988. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bardhan K, Anagnostou T and Boussiotis VA:
The PD1: PD-L1/2 pathway from discovery to clinical implementation.
Front Immunol. 7:5502016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wollenberg B: PD-1 antibodies in
head-and-neck cancer. Lancet. 393:108–109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kansy BA, Concha-Benavente F, Srivastava
RM, Jie HB, Shayan G, Lei Y, Moskovitz J, Moy J, Li J, Brandau S,
et al: PD-1 Status in CD8+T cells associates with survival and
Anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res.
77:6353–6364. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bauml J, Seiwert TY, Pfister DG, Worden F,
Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, et al:
Pembrolizumab for platinum- and cetuximab-refractory head and neck
cancer: Results from a single-arm, phase ii study. J Clin Oncol.
35:1542–1549. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pai SI, Zandberg DP and Strome SE: The
role of antagonists of the PD-1: PD-L1/PD-L2 axis in head and neck
cancer treatment. Oral Oncol. 61:152–158. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
De Felice F, Tombolini M, Abate G, Salerno
F, Bulzonetti N, Tombolini V and Musio D: Prognostic significance
of the neutrophil/lymphocyte ratio in patients with non-human
papilloma virus-related oropharyngeal cancer: A retrospective
cohort study. Oncology. 96:8–13. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang SH, Waldron JN, Milosevic M, Shen X,
Ringash J, Su J, Tong L, Perez-Ordonez B, Weinreb I, Bayley AJ, et
al: Prognostic value of pretreatment circulating neutrophils,
monocytes, and lymphocytes in oropharyngeal cancer stratified by
human papillomavirus status. Cancer. 121:545–555. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chew EY, Hartman CM, Richardson PA,
Zevallos JP, Sikora AG, Kramer JR and Chiao EY: Risk factors for
oropharynx cancer in a cohort of HIV-infected veterans. Oral Oncol.
68:60–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Faraji F, Fung N, Zaidi M, Gourin CC,
Eisele DW, Rooper LM and Fakhry C: Tumor-infiltrating lymphocyte
quantification stratifies early-stage human papillomavirus
oropharynx cancer prognosis. Laryngoscope. 130:930–938. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Patel T, Morrison LK, Rady P and Tyring S:
Epidermodysplasia verruciformis and susceptibility to HPV. Dis
Markers. 29:199–206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Madeleine MM, Carter JJ, Johnson LG, Wipf
GC, Davis C, Berg D, Nelson K, Daling JR, Schwartz SM and Galloway
DA: Risk of squamous cell skin cancer after organ transplant
associated with antibodies to cutaneous papillomaviruses,
polyomaviruses, and TMC6/8 (EVER1/2) variants. Cancer Med.
3:1440–1447. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Castro FA, Ivansson EL, Schmitt M,
Juko-Pecirep I, Kjellberg L, Hildesheim A, Gyllensten UB and
Pawlita M: Contribution of TMC6 and TMC8 (EVER1 and EVER2) variants
to cervical cancer susceptibility. Int J Cancer. 130:349–355. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lazarczyk M, Dalard C, Hayder M, Dupre L,
Pignolet B, Majewski S, Vuillier F, Favre M and Liblau RS: EVER
proteins, key elements of the natural anti-human papillomavirus
barrier, are regulated upon T-cell activation. PLoS One.
7:e399952012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Crequer A, Picard C, Pedergnana V, Lim A,
Zhang SY, Abel L, Majewski S, Casanova JL, Jablonska S, Orth G and
Jouanguy E: EVER2 deficiency is associated with mild T-cell
abnormalities. J Clin Immunol. 33:14–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Colevas AD, Yom SS, Pfister DG, Spencer S,
Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ,
et al: NCCN Guidelines Insights: Head and neck cancers, version
1.2018. J Natl Compr Canc Netw. 16:479–490. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li B and Dewey CN: RSEM: Accurate
transcript quantification from RNA-Seq data with or without a
reference genome. BMC Bioinformatics. 12:3232011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
R Core Team, . R: A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna: 2014
|
|
31
|
Yoshihara K, Shahmoradgoli M, Martinez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen B, Khodadoust MS, Liu CL, Newman AM
and Alizadeh AA: Profiling tumor infiltrating immune cells with
CIBERSORT. Methods Mol Biol. 1711:243–259. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aran D, Hu Z and Butte AJ: xCell:
Digitally portraying the tissue cellular heterogeneity landscape.
Genome Biol. 18:2202017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nagy A, Lanczky A, Menyhart O and Győrffy
B: Validation of miRNA prognostic power in hepatocellular carcinoma
using expression data of independent datasets. Sci Rep. 8:92272018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liang C, Kelsey KT, Mcclean MD,
Christensen BC, Marsit CJ, Karagas MR, Waterboer T, Pawlita M and
Nelson HH: A coding variant in TMC8 (EVER2) is associated with high
risk HPV infection and head and neck cancer risk. PLoS One.
10:e01237162015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Antonsson A, Law MH, Neale RE, Coman WB,
Pryor DI; Study of Digestive Health (SDH), ; Porceddu SV and
Whiteman DC: Variants of EVER1 and EVER2 (TMC6 and TMC8) and human
papillomavirus status in patients with mucosal squamous cell
carcinoma of the head and neck. Cancer Causes Control. 27:809–815.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jablonska S and Majewski S:
Epidermodysplasia verruciformis: immunological and clinical
aspects. Curr Top Microbiol Immunol. 186:157–175. 1994.PubMed/NCBI
|
|
39
|
Majewski S, Jablonska S and Orth G:
Epidermodysplasia verruciformis. Immunological and nonimmunological
surveillance mechanisms: role in tumor progression. Clin Dermatol.
15:321–334. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Patel AS, Karagas MR, Pawlita M, Waterboer
T and Nelson HH: Cutaneous human papillomavirus infection, the
EVER2 gene and incidence of squamous cell carcinoma: A case-control
study. Int J Cancer. 122:2377–2379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Antonsson A, Law MH, Neale RE, Coman WB,
Pryor DI; Study of Digestive Health (SDH), ; Porceddu SV and
Whiteman DC: Erratum to: Variants of EVER1 and EVER2 (TMC6 and
TMC8) and human papillomavirus status in patients with mucosal
squamous cell carcinoma of the head and neck. Cancer Causes
Control. 27:9512016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Henderson NC, Rieder F and Wynn TA:
Fibrosis: From mechanisms to medicines. Nature. 587:555–66. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Su AI, Wiltshire T, Batalov S, Lapp H,
Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, et al:
A gene atlas of the mouse and human protein-encoding
transcriptomes. Proc Natl Acad Sci USA. 101:6062–6067. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Morgan AE, Davies TJ and Mc Auley MT: The
role of DNA methylation in ageing and cancer. Proc Nutr Soc.
77:412–422. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chatterjee S and Ahituv N: Gene regulatory
elements, major drivers of human disease. Annu Rev Genomics Hum
Genet. 18:45–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pu M, Chen J, Tao Z, Miao L, Qi X, Wang Y
and Ren J: Regulatory network of miRNA on its target: Coordination
between transcriptional and post-transcriptional regulation of gene
expression. Cell Mol Life Sci. 76:441–451. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Amaya-Uribe L, Rojas M, Azizi G, Anaya JM
and Gershwin ME: Primary immunodeficiency and autoimmunity: A
comprehensive review. J Autoimmun. 99:52–72. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Iwasaki A and Medzhitov R: Control of
adaptive immunity by the innate immune system. Nat Immunol.
16:343–353. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hammerbacher J and Snyder A: Informatics
for cancer immunotherapy. Ann Oncol. 28 (Suppl-12):xii56–xii73.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kumar BV, Connors TJ and Farber DL: Human
T cell development, localization, and function throughout life.
Immunity. 48:202–213. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Park H, Li Z, Yang XO, Chang SH, Nurieva
R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q and Dong C: A distinct
lineage of CD4 T cells regulates tissue inflammation by producing
interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Scott M, Nakagawa M and Moscicki A: B.
Cell-mediated immune response to human papillomavirus infection.
Clin Diagn Lab Immunol. 8:209–20. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jogdand GM, Mohanty S and Devadas S:
Regulators of Tfh cell differentiation. Front Immunol. 7:5202016.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Renand A, Milpied P, Rossignol J, Bruneau
J, Lemonnier F, Dussiot M, Coulon S and Hermine O: Neuropilin-1
expression characterizes T follicular helper (Tfh) cells activated
during B cell differentiation in human secondary lymphoid organs.
PLoS One. 8:e855892013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Huang Y, Moreau A, Dupuis J, Streubel B,
Petit B, Le Gouill S, Martin-Garcia N, Copie-Bergman C, Gaillard F,
Qubaja M, et al: Peripheral T-cell lymphomas with a follicular
growth pattern are derived from follicular helper T cells (TFH) and
may show overlapping features with angioimmunoblastic T-cell
lymphomas. Am J Surg Pathol. 33:682–690. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Schmitt N, Bentebibel SE and Ueno H:
Phenotype and functions of memory Tfh cells in human blood. Trends
Immunol. 35:436–442. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yasuda K, Takeuchi Y and Hirota K: The
pathogenicity of Th17 cells in autoimmune diseases. Semin
Immunopathol. 41:283–297. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chang SH: T helper 17 (Th17) cells and
interleukin-17 (IL-17) in cancer. Arch Pharm Res. 42:549–559. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Goswami KK, Ghosh T, Ghosh S, Sarkar M,
Bose A and Baral R: Tumor promoting role of anti-tumor macrophages
in tumor microenvironment. Cell Immunol. 316:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Murray PJ: Macrophage Polarization. Annu
Rev Physiol. 79:541–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lefebvre JL, Sanes JR and Kay JN:
Development of dendritic form and function. Annu Rev Cell Dev Biol.
31:741–777. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Cooper LA, Demicco EG, Saltz JH, Powell
RT, Rao A and Lazar AJ: PanCancer insights from the cancer genome
atlas: The pathologist's perspective. J Pathol. 244:512–524. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Dunne EF and Park IU: HPV and
HPV-associated diseases. Infect Dis Clin North Am. 27:765–78. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Goodman A: HPV testing as a screen for
cervical cancer. BMJ. 350:h23722015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wang SS, Gonzalez P, Yu K, Porras C, Li Q,
Safaeian M, Rodriguez AC, Sherman ME, Bratti C, Schiffman M, et al:
Common genetic variants and risk for HPV persistence and
progression to cervical cancer. PLoS One. 5:e86672010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yamada Y, Arai T, Kojima S, Sugawara S,
Kato M, Okato A, Yamazaki K, Naya Y, Ichikawa T and Seki N:
Regulation of antitumor miR-144-5p targets oncogenes: Direct
regulation of syndecan-3 and its clinical significance. Cancer Sci.
109:2919–2936. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lu P, Ding Q, Ding S, Fan Y, Li X, Tian D
and Liu M: Transmembrane channel-like protein 8 as a potential
biomarker for poor prognosis of hepatocellular carcinoma. Mol Clin
Oncol. 7:244–248. 2017.PubMed/NCBI
|
